Jeito Capital Archives | Be Korea-savvy

Home / Posts tagged Jeito Capital

Jeito Capital Co-leads EUR 65 Million (USD 71 M) Financing in Corteria Pharmaceuticals, a French Biopharmaceutical Company Developing Novel Treatments for Cardiovascular Diseases

Paris, France, Sept. 7 (Korea Bizwire) – Jeito Capital (“Jeito”), a global leading investment firm dedicated to healthcare and biopharma, announced today that it is co-leading a EUR 65m (USD 711M) Series A financing round in Corteria Pharmaceuticals (“Corteria” or the “Company”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations. [...]

Jeito Capital Leads a $105 Million Series C Financing in Alentis Therapeutics to Advance Transformational Medicines for Claudin-1 in Cancer & Fibrosis

Paris, France, April 13 (Korea Bizwire) - Jeito Capital (“Jeito”), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has led a $105 million (€96 million) Series C financing in Alentis Therapeutics (“Alentis” or the “Company”), a clinical-stage biotech spun out of INSERM, based in Basel (Switzerland) with [...]

Jeito Capital Co-leads a EUR 104 Million Financing in Noema Pharma, a Clinical-stage Biopharma Company Targeting Debilitating Central Nervous System Disorders

Paris, France, March 7 (Korea Bizwire) - Jeito Capital (“Jeito”), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has co-led a EUR 104 million (CHF 103 million, approx. USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders. [...]

Jeito Capital Strengthens Its Support in Pulmocide with Participation in $52 Million Financing

Paris, France, Dec. 6 (Korea Bizwire) - Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, announced today its participation in a $52 million Series C extension financing round in portfolio company Pulmocide, a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory [...]

Jeito Capital Demonstrates European Biopharma Leadership with First Exit with AstraZeneca Acquisition of Neogene Therapeutics

Paris, France, Nov. 29 (Korea Bizwire) - Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, is pleased to announce the realization of its investment in Neogene Therapeutics, Inc. (“Neogene Therapeutics” or “Neogene”) to AstraZeneca a global, science-led biopharmaceutical company. Neogene is a global clinical-stage company pioneering the discovery, development, and manufacturing [...]

Jeito Capital Co-leads EUR 50 Million Financing in CatalYm, a Clinical-stage Biopharma Company Developing Novel Immunotherapies for Patients with Cancer

Paris, France, Nov. 22 (Korea Bizwire) - Jeito Capital (“Jeito”), a leading independent international private equity firm dedicated to healthcare and biopharma, announced today that it has co-led a EUR 50 million Series C financing round in CatalYm, a clinical-stage biopharmaceutical company developing novel immunotherapies to fight cancer. The oversubscribed financing was co-led by Brandon Capital with [...]

Jeito Capital Becomes a Significant Investor in HI-Bio, a Clinical-stage Biotech Company Developing Targeted Therapies for Patients with Severe Immune-mediated Diseases

Paris, France, Nov. 1 (Korea Bizwire) - Jeito Capital (“Jeito”), a leading independent international private equity firm dedicated to biopharma, announced today that it has participated in the $120 million financing of Human Immunology Biosciences (HI-Bio™), a clinical-stage biotech company developing targeted therapies for patients suffering from severe immune-mediated diseases (IMD). Jeito Capital joins a syndicate of world class [...]

Jeito Capital Co-leads EUR 80 Million Series B Financing in European Oncology Company, Precirix

Paris, France, March 16 (Korea Bizwire) – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led an investment of €80 million in Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology. The Belgian biotech company was created in 2014 as a spin-off from the Vrije Universiteit [...]

Jeito Capital Co-leads $65 Million Series A Financing in EyeBio

Paris, France, Feb. 22 (Korea Bizwire) – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $65 million Series A financing round in EyeBiotech Limited (“EyeBio”), a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases. The Series [...]

Jeito Capital Co-leads $156 Million Oversubscribed Series B financing in Quell Therapeutics

Paris, France, Nov. 29 (Korea Bizwire) – Jeito Capital (“Jeito”), a leading independent private equity firm dedicated to biotech and biopharma, today announces that it has co-led a $156 million oversubscribed Series B financing round in Quell Therapeutics (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by [...]